Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | Agents under investigation for the treatment of TA-TMA

Eleni Gavriilaki • 16 Feb 2024
CAR-T Meeting 2024
General Antibodies Pegcetacoplan Ravulizumab

In this video, Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, briefly discusses updates in the treatment of transplant-associated thrombotic microangiopathy (TA-TMA) post-transplantation, highlighting some agents being investigated in ongoing clinical trials. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Pfizer and Jazz Pharmaceuticals
Honoraria: Alexion, AstraZeneca, Omeros, Sanofi, Sobi

More from Eleni Gavriilaki

1:03
Cognitive impairment in patients receiving CAR T-cell therapy
Eleni Gavriilaki • 16 Feb 2024
0:52
Long-term complications in patients with hematological malignancies post-SCT
Eleni Gavriilaki • 11 Dec 2023
1:19
The potential of caplacizumab in the treatment of aTTP
Eleni Gavriilaki • 11 Dec 2023
1:51
Targeting complement to treat PNH and other hematologic diseases
Eleni Gavriilaki • 11 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals